Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5111-5119

  Rocca, Andrea ^a,b   Cancello, Giuseppe ^a   Bagnardi, Vincenzo ^a,c,d   Sandri, Maria Teresa ^a   Torrisi, Rosalba ^a   Zorzino, Laura ^a   Viale, Giuseppe ^a,e   Pietri, Elisabetta ^a   Veronesi, Paolo ^a,e   Dellapasqua, Silvia ^a   Ferrucci, Francesco ^a   Luini, Alberto ^a   Johansson, Harriet ^a   Ghisini, Raffaella ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d RICERCA SUL SISTEMA ENERGETICO RSE S P A   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; EGFR; HER2; Surgery; VEGF

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GONADORELIN; LETROZOLE; METHOTREXATE; TAMOXIFEN; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST BIOPSY; BREAST CANCER; EARLY CANCER; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PERIOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75149166478     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Klijn JG, Berns PM, Schmitz PI and Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 3-17, 1992.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressier L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
4. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO and Blarney RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki-67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018-1023, 1993.
5. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G and Colnaghi MI: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923, 1993.
6. Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, Sinclair CS, Pearsall RS, Green PJ, Yee D, Lampland AL, Balasubramaniam S, Crossley TD, Magnuson TR, James CD and Maihle NJ: Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 71: 1-20, 2001.
7. Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387, 2000.
8. Hunts JH, Shimizu N, Yamamoto T, Toyoshima K, Merlino GT, Xu YH and Pastan I: Translocation chromosome 7 of A431 cells contains amplification and rearrangement of EGF receptor gene responsible for production of variant mRNA. Somat Cell Mol Genet 11: 477-484, 1985.
9. Sandri MT, Johansson H, Colleoni M, Zorzino L, Passerini R, Orlando L and Viale G: Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 24(2C): 1261-1266, 2004.
10. Carney WP, Leitzel K, Ali S, Neumann R and Lipton A: HER-2/neu diagnostics in breast cancer. Breast Cancer Res 9(3): 207, 2007.
11. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992.
12. Engels K, Fox SB, Whitehouse RM, Gatter KC and Harris AL: Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 181: 207-212, 1997.
13. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T and Tominaga T: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2: 821-826, 1996.
14. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
15. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr and Le XF: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25(52): 6986-6996, 2006.
16. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A and Ménard S: Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362(9383): 527-533, 2003.
17. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF and van de Water L: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176: 1375-1379, 1992.
18. Reid SE, Kaufman MW, Murthy S and Scanlon EF: Perioperative stimulation of residual cancer cells promotes local and distant recurrence of breast cancer. J Am Coll Surg 185: 290-306, 1997.
19. Abramovitch R, Marikovsky M, Meir G and Neeman M: Stimulation of tumour growth by wound-derived growth factors. Br J Cancer 79(9-10): 1392-1398, 1999.
20. Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A and Goldhirsch A: Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat 93(1): 35-40, 2005.
21. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY and Morris DL: Automated assay for HER-2/neu in serum. Clin Chem 46: 175-182, 2000.
22. Harrell FE Jr, Lee KL and Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387, 1996.
23. Grambsch P and Therneau T: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526, 1994.
24. Salvadori B, Pinzani P, Distante V, Casella D, Bianchi S, Paglierani M, Vezzosi V, Neumann R, Cataliotti L, Pazzagli M and Orlando C: Comparison of pre- and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer. Clin Chem 51: 254-256, 2005.
25. Kandl H, Seymour L and Bezwoda WR: Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 70: 739-742, 1994.
26. Molina R, Jo J, Filella X et al: C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 16: 2295-2300, 1996.
27. Willsher PC, Beaver J, Bell JA, Ellis IO, Blarney RW and Robertson JF: Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 40: 251-255, 1996.
28. Imoto S, Wada N, Hasebe T, Ochiai A and Kitoh T: Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. Int J Cancer 120: 357-361, 2007.
29. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, Farms B and Ballesta AM: Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 23(2A): 1043-1050, 2003.
30. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L and Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135, 1995.
31. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hösch S and Hayes DF: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518-2525, 1997.
32. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W and Allard J: Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467-1472, 2002.
33. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL and Hortobagyi GN: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808, 2002.
34. Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H, Tsai KL, Kim M, Locker J, Zhang ZY and Segall JE: ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 66: 1418-1426, 2006.
35. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B and Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523-1530, 1997.
36. Brattström D, Bergqvist M, Hesselius P, Larsson A, Lamberg K, Wernlund J, Brodin O and Wagenius G: Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 37(1): 57-63, 2002.
37. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK and Lee SD: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10(4): 355-362, 2003.
38. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Due A and Blay JY: Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88(11): 1721-1726, 2003.
39. Asgeirsson KS, Agrawal A, Allen C, Hitch A, Ellis IO, Chapman C, Cheung KL and Robertson JF: Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 9(6): R75, 2007.
40. Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W and Lipton A: Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer 107: 2337-2345, 2006.
41. Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G and Colleoni M: Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 110(3): 509-517, 2007.
42. Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN and Maihle NJ: Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res 65(8): 3059-62, 2005.
43. Witzel I, Thomssen C, Krenkel S, Wilczak W, Bubenheim M, Pantel K, Neumann R, Jänicke F and Müller V: Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers 21(3): 131-140, 2006.